Syros Pharmaceuticals, Inc.

Sutro Biopharma announced after the stock market closed on 13 March that as a result of a strategic portfolio review the company will end development of its one and only clinical-stage antibody drug c

Syros Pharmaceuticals’ tamibarotene has likely reached a dead end as the company announced that the Phase III trial in higher-risk myelodysplastic syndrome (MDS) did not meet its primary endpoint, the

Navigator Medicines unveiled its plans to develop novel medicines for complex, heterogeneous autoimmune diseases on 27 August, revealing that it has raised $100m in series A funding from RA Capital M

The decision by Syros Pharmaceuticals, Inc. to discontinue enrollment in the Phase II SELECT-AML-1 trial of tamibarotene in newly diagnosed acute myeloid leukemia (AML) patients unfit for intensive